 | • レポートコード：MRC2303I0183 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の毒性学における薬剤スクリーニング市場規模が、予測期間中（2022年-2027年）に年平均11.25%で成長すると予測しています。本書では、毒性学における薬剤スクリーニングの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、 検査種類別（インビトロ、インビボ、インシリコ）分析、製品別（器械、試薬及び消耗品、動物モデル、ソフトウェア、その他）分析、用途別（免疫毒性、全身毒性、発生及び殖毒性（DART）、内分泌かく乱、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Agilent Technologies Inc.、Bio-Rad Laboratories Inc.、BioReliance Inc. （Merck）、Charles River Laboratories International Inc.、Enzo Life Sciences Inc.、Eurofins Scientific、Danaher、Laboratory Corporation of America Holdings、Promega Corporation、The Jackson Laboratoryなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の毒性学における薬剤スクリーニング市場規模：検査種類別 - インビトロ検査の市場規模 - インビボ検査の市場規模 - インシリコ検査の市場規模 ・世界の毒性学における薬剤スクリーニング市場規模：製品別 - 器械の市場規模 - 試薬及び消耗品の市場規模 - 動物モデルの市場規模 - ソフトウェアの市場規模 - その他製品の市場規模 ・世界の毒性学における薬剤スクリーニング市場規模：用途別 - 免疫毒性における市場規模 - 全身毒性における市場規模 - 発生及び殖毒性（DART）における市場規模 - 内分泌かく乱における市場規模 - その他用途における市場規模 ・世界の毒性学における薬剤スクリーニング市場規模：地域別 - 北米の毒性学における薬剤スクリーニング市場規模 アメリカの毒性学における薬剤スクリーニング市場規模 カナダの毒性学における薬剤スクリーニング市場規模 メキシコの毒性学における薬剤スクリーニング市場規模 … - ヨーロッパの毒性学における薬剤スクリーニング市場規模 ドイツの毒性学における薬剤スクリーニング市場規模 イギリスの毒性学における薬剤スクリーニング市場規模 フランスの毒性学における薬剤スクリーニング市場規模 … - アジア太平洋の毒性学における薬剤スクリーニング市場規模 中国の毒性学における薬剤スクリーニング市場規模 インドの毒性学における薬剤スクリーニング市場規模 日本の毒性学における薬剤スクリーニング市場規模 … - 中東・アフリカの毒性学における薬剤スクリーニング市場規模 GCC諸国の毒性学における薬剤スクリーニング市場規模 南アフリカの毒性学における薬剤スクリーニング市場規模 … - 南米の毒性学における薬剤スクリーニング市場規模 ブラジルの毒性学における薬剤スクリーニング市場規模 アルゼンチンの毒性学における薬剤スクリーニング市場規模 … - その他地域の毒性学における薬剤スクリーニング市場規模 ・競争状況 ・市場機会・将来の動向 |
The toxicology drug screening market is expected to register a CAGR of 11.25% during the forecast period (2022-2027).
Due to the current COVID-19 situation and the need to develop vaccines and effective treatment methods, various research laboratories and biopharmaceutical industries have extensively used toxicological screening methods in drug development. According to an article published by the Science Advisory Board in July 2020, researchers are using a strain of SARS-CoV-2 that can infect mice to produce a new mouse model of infection and facilitate several in vivo tests of COVID-19 vaccine candidates and therapies. However, there is a significant decline in non-COVID-19 related research, which is likely to affect the market growth.
In vitro, in vivo, and in silico are the different techniques that are used to assess drug toxicity and confirm the safety of the drug in the drug discovery and development process, i.e., clinical and pre-clinical trials. Toxicity testing has become well-developed due to various advanced technologies aiding the process, and it is currently anticipated to take advantage of promising revolutions in the fields of biotechnology and pharmaceuticals.
The studied market is driven by three major factors: increasing research and development expenditure, technological advancements in toxicity screening, and rising demand for toxicological drug screening. In 2019, Roche incurred an R&D expense of CHF 11.7 billion, while Johnson & Johnson invested USD 11.36 billion in R&D. Additionally, the recent technological developments by the market players and researchers are contributing to the growth of the market studied. For instance, in the research study published in Biofabrication in 2020, a primary human cell- and stem cell-derived 3D organoid technology was employed to screen a panel of drugs that were recalled from the market by the US FDA. The platform comprises multiple tissue organoid types that remain viable for at least 28 days in vitro. Earlier, in August 2019, Covance launched a laboratory solution within its functional service provider (FSPx) offering, which expanded the capabilities of its clinical analytics services and clinical operations.
The rising prevalence of various diseases is also fueling the market demand for different toxicological screening procedures. This is because the rise in disease incidence prompts companies to develop new therapeutics. As per the World Health Organization (WHO), the burden of chronic diseases is increasing. It has been observed that almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity, and diabetes, which are showing increasing trends. The WHO 2019 Report stated that chronic diseases kill 41 million people yearly, equivalent to 71% of all deaths globally.
Cancer is the second leading cause of death globally. It was responsible for an estimated 10 million deaths in 2020, per the WHO report for 2021. Globally, about 1 in 6 deaths was due to cancer. In addition, approximately 70% of deaths from cancer occur in low- and middle-income countries. Cancer Research UK also predicted that if the recent trends in incidence of major cancers and population growth are consistent, there may be 27.5 million new cancer cases worldwide each year by 2040. Thus, the rising burden of these diseases is expected to fuel market growth.
The applications of toxicity testing are set to increase with advances in biotechnology and pharmaceuticals, resulting in a demand for the same. Several emerging fields and techniques are providing new insights into understanding biological responses to chemicals in human tissues. Furthermore, there is an increase in pharmaceutical R&D spending globally. In 2020, the global spending on R&D reached a record high of almost USD 1.7 trillion, according to the UNESCO Institute for Statistics. The key drivers for market growth are the increasing R&D activities, the technological advancements in toxicology drug screening, and the rise in demand for toxicology drug screening in the pharmaceutical and biotechnology industries. However, the long duration of sample testing and stringent government regulations on the toxicological testing of human drug molecules are expected to hinder market growth over the forecast period.
Toxicology Drug Screening Market Trends
In-silico Segment Expected to Register Robust Growth
The in-silico segment holds a significant market share in the toxicology drug screening market and is anticipated to show robust growth over the forecast period. In silico methods help identify drug targets via bioinformatics tools. They are also used to analyze the target structures to generate candidate molecules, find possible binding/active sites, check their drug-likeness, and further optimize the molecules to improve their binding characteristics.
As per the 2019 estimates of the US Food and Drug Administration (FDA), pipeline drugs experienced a growth rate of 6%, compared to 2.7% in 2018. Currently, the drug discovery process is being revolutionized by the deployment of various proteomics, genomics, bioinformatics, and efficient technologies like in silico ADMET screening and structure-based drug design, virtual screening, and de novo design, which help in the detection of drug toxicology.
The increasing research and development activities, technological advancements in drug screening, and rise in demand for toxicology drug screening in the pharmaceutical and biotechnology industries are the key driving factors of the in-silico segment.
The in-silico platform is considered a potential tool in various COVID-19-related research in predicting the immune responses of potential candidate vaccines. The Universal Immune System Simulator (UISS) in silico platform has a strong potential to predict the outcome of a vaccination strategy against the COVID-19 virus. It has been frequently employed in various researches to speed up and drive the discovery pipeline of the vaccine. Hence, the segment is expected to show positive growth during the forecast period.
North America Expected to Hold Significant Market Share
North America is expected to hold a significant market share in the global toxicology drug screening market due to the growing research and development activities in this region to detect toxicity levels in the human body at early stages. The research and development in this region reached a plateau, as these trials are being outsourced to other regions, like Asia. However, the increasing R&D investments and rising demand for drug development are the major factors driving the market growth. The pharmaceutical companies in North America spend more money, time, and energy on R&D than most other pharmaceutical companies in other regions. According to an article published by the National Center for Science and Engineering Statistics (2020), the 42 federally funded research and development centers (FFRDCs) in the United States spent USD 23.5 billion on research and development in FY 2020, recording an annual increase of 3.4%. This increase in expenditure is primarily driven by the focus on having the edge over their competitors and the high returns gained on newly developed products.
Also, the R&D budgets of the pharmaceutical companies have increased in the past few years, owing to the rising burden of diseases, complex molecules, and therapy segments. According to the data from the Pharmaceutical Research and Manufacturers of America (2019), the research and development expenditure of the US pharmaceutical industry increased from 15.2 billion in 1995 to 79.6 billion in 2018.
Moreover, due to the presence of established market players and the focused R&D of new drugs, the market for clinical trials in the United States has been growing, which is also impacting the toxicology drug screening market positively. According to the Biotechnology Innovation Organization, in 2019, around 50 novel drugs were approved by the Center for Drug Evaluation and Research (CDER). Furthermore, technical advancements and supportive government regulations have led to the rapid development of innovative and cost-effective testing. The presence of a well-established healthcare infrastructure is also fueling the growth of the market.
Toxicology Drug Screening Market Competitor Analysis
The toxicology drug screening market is consolidated and moderately competitive with the presence of a few key players. Some companies currently dominating the market are Agilent Technologies Inc., Bio-Rad Laboratories Inc., Eurofins Scientific, Danaher, Laboratory Corporation of America Holdings, BioReliance Inc., Thermo Fisher Scientific Inc., and Enzo Life Sciences Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Activities
4.2.2 Technological Advancements in Toxicology Drug Screening
4.2.3 Rise in Demand for Toxicology Drug Screening in Pharmaceuticals and Biotechnology
4.3 Market Restraints
4.3.1 Longer Time for Sample Testing
4.3.2 Regulatory Issues Regarding Approval of Healthcare Molecule
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Testing Type
5.1.1 In Vitro
5.1.2 In Vivo
5.1.3 In Silico
5.2 By Product
5.2.1 Instruments
5.2.2 Reagents and Consumables
5.2.3 Animal Models
5.2.4 Software
5.2.5 Other Products
5.3 By Application
5.3.1 Immunotoxicity
5.3.2 Systemictoxicity
5.3.3 Developmental and Reproductive Toxicity (DART)
5.3.4 Endocrine Disruption
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 BioReliance Inc. (Merck)
6.1.4 Charles River Laboratories International Inc.
6.1.5 Enzo Life Sciences Inc.
6.1.6 Eurofins Scientific
6.1.7 Danaher
6.1.8 Laboratory Corporation of America Holdings
6.1.9 Promega Corporation
6.1.10 The Jackson Laboratory
6.1.11 Thermo Fisher Scientific Inc.
6.1.12 Wuxi AppTec
6.1.13 Waters
6.1.14 Selvita
6.1.15 TECHCOMP GROUP (SCION INSTRUMENTS)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS